Global Anti-Obesity Prescription Drugs Market to Gain Rapid Expansion during 2017-2026: Liraglutide Drug Class Anticipates to Lead

Obesity is largely considered a lifestyle disease that has become the second leading cause of preventable deaths. This disease needs proper medical attention. Prescription weight loss medication is used by doctors and physicians to cure obesity. In the present time, growing prevalence of obesity globally has led to an upsurge in demand for anti-obesity prescription drugs globally. Owing to this, the global anti-obesity prescription drugs market is expected to witness a moderate growth in the coming years, states a new report added to the broad repository of Market Research Hub (MRH). The study is titled as “Anti-Obesity Prescription Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2026”, and presents a comprehensive assessment of the worldwide market for anti-obesity prescription drugs on several important parameters. Moreover, the primary regions are analyzed for the purpose of evaluating the impact of the different factors mentioned in the research report.

Request Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1391914

Key Findings from the Report

As mentioned in the research report, the global anti-obesity prescription drugs market is projected to replicate a CAGR of 4.8% over the forecast period, 2017-2026. At present, based on the drug class, the liraglutide segment is projected to make significant revenues, representing more than US$ 100 Mn by 2026-end.

Increasing consumption of unhealthy food and beverage products is anticipated to rev up demand for anti-obesity prescription drugs globally. As the unhealthy food products are rich in cholesterol, the surge in consumption of unhealthy food and beverage products continues to increase obesity, which leads to the adoption of anti-obesity drugs. These prescription drugs are not recommended as the primary source of achieving weight loss, but as an aid when diet changes and exercise simply won't help the patient out of the danger zone.

Obesity has continued to remain a major side-effect of consuming psychotropic drugs. Growing prevalence of depression has led to increased consumption of the psychotropic drugs. Growing prevalence of obesity due to increasing side-effects of psychotropic drugs has led to an upsurge in demand for obesity management. These combined factors are contributing toward the market growth for anti-obesity prescription drugs.

However, Increasing preference for practicing yoga to lose weight has led to reduced reliance of obese population on anti-obesity medications. Moreover, the obese persons prefer including sugar-free food and beverages in their diet plan. These factors are projected to inhibit the global market growth of anti-obesity prescription drugs.

Browse Full Report with TOC@ https://www.marketresearchhub.com/report/anti-obesity-prescription-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2026-report.html

Segmental Analysis

For a clear understanding of the market, the global anti-obesity prescription drugs market is mainly segmented into drug class, age group, distribution channel, and region. Drug classes highlighted in the report include Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate and Liraglutide. On the other hand, based on age group, adult age group anticipated to generate significant revenues, finds study.

Another vital section of the report is competitive landscape featuring some of the top companies, their products and business strategies, and their standing in the global market. Key players in the global anti-obesity prescription drugs market are VIVUS, Inc, Orexigen Therapeutics, Inc, Novo Nordisk A/S, F Hoffmann La Roche Ltd and Arena Pharmaceuticals, Inc.

Enquire About this Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1391914